Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Akebia Therapeutics (Nasdaq: AKBA) announced that Chief Financial and Business Officer Erik Ostrowski and Chief Commercial Officer Nicholas Grund will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 7:35 AM ET in New York.

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced that Chief Financial and Business Officer Erik Ostrowski and Chief Commercial Officer Nicholas Grund will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 7:35 AM ET in New York.

A live and 90-day replay webcast will be available via Akebia's investor website.

Argus May 28 session

+1.94% close to close Open Argus

Details

News Market Reaction – AKBA

On May 28, the day this news came out, AKBA closed 1.94% above the previous close.

Data tracked by StockTitan Argus for the May 28 session.

Market Context

This announcement highlights Akebia’s participation in the 2026 Jefferies Global Healthcare Conferen...

Analysis

This announcement highlights Akebia’s participation in the 2026 Jefferies Global Healthcare Conference, with management presenting on June 4, 2026 and a webcast replay available for 90 days. It mainly expands investor outreach rather than adding new financial or clinical data. Given recent history of sharp moves around earnings and trial updates, investors may focus on how future results and pipeline milestones build on the themes discussed at this event.

Key Figures

Conference presentation time: 7:35 AM ET Webcast replay period: 90 days

Conference presentation time

7:35 AM ET

Jefferies Global Healthcare Conference presentation on June 4, 2026

Webcast replay period

90 days

Replay available following the conference presentation

Historical Context

5 past events · Latest: May 07

5 events

1. May 07

   Q1 2026 earnings

   24h Move

   -20.3%

   Reported Q1 net loss and revenue decline versus prior year, highlighting pressure.

2. May 04

   Inducement grants

   24h Move

   -3.3%

   Announced stock option inducement grants to new employees under Nasdaq rules.

3. May 04

   Clinical analysis

   24h Move

   +7.1%

   Post‑hoc win statistics analysis showed significant mortality and hospitalization benefit.

4. Apr 30

   Earnings date notice

   24h Move

   +1.4%

   Set date and webcast details for upcoming Q1 2026 earnings call.

5. Apr 13

   Phase 1 initiation

   24h Move

   +5.0%

   First participants dosed in Phase 1 trial of AKB‑9090 for AKI.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast will also be available for 90 days following the presentation.

The 2026 Jefferies Global Healthcare Conference will take place June 2-4, 2026, in New York, NY.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. 

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Akebia Therapeutics (AKBA) present at the 2026 Jefferies Global Healthcare Conference?

Akebia Therapeutics will present on June 4, 2026, at 7:35 AM ET. According to Akebia, the presentation is part of the 2026 Jefferies Global Healthcare Conference held June 2-4, 2026, in New York, NY.

Who will present for Akebia Therapeutics (AKBA) at the 2026 Jefferies Global Healthcare Conference?

Akebia will be represented by Erik Ostrowski and Nicholas Grund at the conference. According to Akebia, Ostrowski is Chief Financial and Business Officer, and Grund is Chief Commercial Officer, both speaking at the June 4, 2026 session.

How can investors access the Akebia Therapeutics (AKBA) webcast from the 2026 Jefferies conference?

Investors can access a live webcast through the Investors section of Akebia’s website. According to Akebia, a replay of the conference presentation will remain available on the site for 90 days following the June 4, 2026 event.

Where is the 2026 Jefferies Global Healthcare Conference featuring Akebia Therapeutics (AKBA) being held?

The 2026 Jefferies Global Healthcare Conference will take place in New York, NY. According to Akebia, its leadership team will present there on June 4, 2026, at 7:35 AM ET as part of the multi-day healthcare investor event.

What is the significance of Akebia Therapeutics (AKBA) presenting at the 2026 Jefferies Global Healthcare Conference?

Presenting at the Jefferies conference offers Akebia visibility with healthcare investors and analysts. According to Akebia, senior executives will share the company’s kidney disease-focused mission and business updates during the June 4, 2026 New York session and webcast.